Palivizumab Treatment of Respiratory Syncytial Virus Infection after Allogeneic Hematopoietic Stem Cell Transplantation
Open Access
- 15 October 2007
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 45 (8), 1019-1024
- https://doi.org/10.1086/521912
Abstract
Among 40 allogeneic stem cell transplant recipients who developed symptomatic respiratory syncytial virus infection, including 22 patients with lower respiratory tract infection, 19 received palivizumab (9 of whom had upper respiratory tract disease). Palivizumab did not prevent progression to lower respiratory infection and had no impact on the overall survival rate.Keywords
This publication has 15 references indexed in Scilit:
- Randomized Controlled Multicenter Trial of Aerosolized Ribavirin for Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic Cell Transplant RecipientsClinical Infectious Diseases, 2007
- Frequent Detection of Respiratory Viruses in Adult Recipients of Stem Cell Transplants with the Use of Real-Time Polymerase Chain Reaction, Compared with Viral CultureClinical Infectious Diseases, 2005
- Low mortality rates related to respiratory virus infections after bone marrow transplantationBone Marrow Transplantation, 2003
- Community-acquired respiratory syncytial virus and parainfluenza virus infections after hematopoietic stem cell transplantation: The Fred Hutchinson Cancer Research Center experienceTransplantation and Cellular Therapy, 2001
- Community respiratory virus infections in bone marrow transplant recipients: The M.D. Anderson Cancer Center experienceTransplantation and Cellular Therapy, 2001
- Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow TransplantationBone Marrow Transplantation, 2001
- Phase 1 Evaluation of the Respiratory Syncytial Virus–Specific Monoclonal Antibody Palivizumab in Recipients of Hematopoietic Stem Cell TransplantsThe Journal of Infectious Diseases, 2001
- Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation – a compassionate use experienceBone Marrow Transplantation, 2000
- Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk InfantsPediatrics, 1998
- Development of a Humanized Monoclonal Antibody (MEDI‐493) with Potent In Vitro and In Vivo Activity against Respiratory Syncytial VirusThe Journal of Infectious Diseases, 1997